ArticleHuman vaccines & immunotherapeutics2026
Cost-effectiveness of finotonlimab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in China.
Huihui Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.